Mabwell completes Hong Kong IPO
Mabwell Bioscience completed its dual listing on the Hong Kong Stock Exchange on April 28. The company previously secured a USD 600 million licensing deal with Alphabet subsidiary Calico Life Sciences. It reported 2025 revenue of RMB 658.7 million, up 230% YoY.